MaaT Pharma
@MaaT_Pharma
Followers
2K
Following
3K
Statuses
3K
Our mission is to develop #microbiome-based therapies targeting mortality and comorbidities associated with cancer treatments.
Lyon, France
Joined September 2015
📄 [Press release] – MaaT Pharma is proud to announce positive Phase 3 results evaluating MaaT013 in treating acute Graft-versus-Host Disease with gastrointestinal involvement (#aGvHD). Topline Data highlights: ✅ Primary endpoint met: significant GI-ORR at Day 28 of 62%, exceeding the expected response rate of 38%. ✅ Improved survival: 54% probability of survival at 1 year driven by clinical response. ✅ Next steps: Anticipating MAA submission in Europe by mid-2025, ahead of schedule! Thank you to the patients and investigators—this milestone wouldn’t have been possible without your participation. 👉 #clinicaltrials #oncology #GvHD #innovation #MaaT013 #Phase3 #PositiveData #aGvH #microbiome
0
5
11
📰 – Proud to keep sharing the positive Phase 3 data in #aGvHD through media coverage, this time featured in @PharmaScrip! Thanks to Alaric DeArment for reporting on our milestones, including the Phase 3 data and our EMA filing. 👉 Read the full article: #Oncology #Microbiome #GvHD #ClinicalTrials
0
2
3
💡 [#WorldCancerDay 2025] - There’s never been a more exciting time in #microbiome #research, especially in #oncology. We’re proud that our ARES trial is contributing to the field, and to a potential breakthrough treatment. Learn more from Professor @Mohty_EBMT on what it could mean for #patients. #Oncology #Hematology #aGvHD #Cancer
1
5
9
📰 - We're proud to see our positive Phase 3 Topline results featured in @LesEchos. Thank you to Myriam Chauvot from @LesEchos for highlighting the promising outcomes of our Phase 3 trial for MaaT013 to treat acute Graft-versus-Host Disease with gastrointestinal involvement (#aGvHD). 👉 See the article here:
0
2
4
RT @Mohty_EBMT: Un webinaire d’information en Français a destination des patients et des familles. Inscription gratuite au:
0
5
0
📰 - 𝗠𝗼𝗿𝗲 𝗚𝗿𝗲𝗮𝘁 𝗠𝗲𝗱𝗶𝗮 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗣𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗧𝗼𝗽𝗹𝗶𝗻𝗲 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗗𝗮𝘁𝗮! We’re thrilled to see our positive Phase 3 trial results for MaaT013 covered by Joshua Silverwood from @TrialsArena! 👉 Read the full article here:
0
1
3
📰 - MaaT Pharma in @FierceBiotech! Proud to see our latest achievement covered in @FierceBiotech with Nick Paul Taylor highlighting our positive Phase 3 results evaluating MaaT013 in treating acute Graft-versus-Host Disease with gastrointestinal involvement (#aGvHD). 👉 Read the full article here:
0
1
4
💡 What does recent data tell us about the potential for targeting #aGvHD through the #microbiome? ICYMI, learn more about our Phase 3 results from Professor @Mohty_EBMT:
0
3
5
RT @OncLive: The phase 3 ARES study, evaluating MaaT013 in patients with acute GVHD with gastrointestinal involvement after treatment refra…
0
6
0
📅 [#EVENT] – Join Alexandre Kiss, Europe Medical Advisor for Oncology and Hematology at MaaT Pharma, at the 17th “Journée Greffe” of @paoli_calmettes, taking place on January 25, in Marseille, France. This annual event has become a key moment to reflect on and shape the future of #transplant programs. This day of information and sharing brings together patients, caregivers and medical experts for impassioned debates. 📍 Les Jardins du Pharo – Marseille #aGvHD #GvHD #BloodCancers #HSCT
0
4
4
📅 [#EVENT] - Join Jonathan CHRIQUI, Chief Business Officer of MaaT Pharma, at the 9th Annual Microbiome Movement Summit event taking place on January 28 to 30 in Barcelona, Spain. Jonathan will be sharing our positive Phase 3 results evaluating MaaT013 in treating acute Graft-versus-Host Disease with gastrointestinal involvement (#aGvHD). 👉Learn more: #microbiome #research #innovation #microbiota #MicrobiomeMovement
0
3
2
👏Proud to see Frederic Fasano, our deputy CEO presenting the positive topline results for our Phase 3 in acute GvHD at Journée Microbiotes et Santé organized by @Lyonbiopole #JMS2025
0
3
4
Kicking off the Journée Microbiotes et Santé organized by @Lyonbiopole with our CEO @HAffagard discussing with Cancer Parients Europe @CancerPatientsE and Prof. Michallet @CHUdeLyon on advancing clinical trials with microbiome drug candidates. #JMS2025 #microbiome
0
1
3
Hervé Affagard @HAffagard presenting the competition global landscape for #microbiome companies and describing late-stage drug candidates at Journée Microbiotes et Santé #JMS2025 by @Lyonbiopole
0
3
6
📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif du deuxième DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 👉 #Microbiote #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2
0
2
4
📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT🩸 #Microbiome #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2
0
4
5
RT @MTIG_News: .@MaaT_Pharma 's MaaT013 has the potential to be the first approved third-line treatment option & transform the survival out…
0
4
0
📅 EN [EVENT] – Proud to be sponsor of the "Journée #Microbiotes et #Santé" organized by @Lyonbiopole! @HAffagard, MBA, Eng., CEO and co-founder of MaaT Pharma, and Frederic Fasano, Deputy Chief Executive Officer, will discuss our Positive Phase 3 results in hemato-oncology and comment on the latest advancements in the #microbiota industry. Click here to register 👉 📅 Thursday, January 23, 2025 📍 Cité Internationale de la Gastronomie de Lyon __________ 📅 FR [EVENEMENT] – Fière de sponsoriser la Journée #Microbiotes & #Santé organisée par @Lyonbiopole ! @HAffagard, MBA, Eng., CEO et co-fondateur de MaaT Pharma, et Frederic Fasano, Directeur Général Adjoint, présenteront les données positives de Phase 3 en hémato-oncologie et commenteront les dernières innovations dans l’industrie du #microbiote. Pour s’inscrire cliquez ici 👉 📅 Jeudi 23 janvier 2025 📍 Cité internationale de la Gastronomie de Lyon
0
1
5
RT @HAffagard: Steep streets of #SanFrancisco are like the entrepreneur's journey: full of uphill climbs, unexpected turns, and rewarding v…
0
3
0
🎥 Behind the scenes in San Francisco! MaaT Pharma’s CEO, @Herve Affagard @HAffagard sat down today with @FierceBiotech 's Rebecca Willumson @RebeccaEFriend during #JPM2025 for an exclusive interview. They discussed our exciting Phase 3 ARES data announcement and what’s ahead for MaaT Pharma in 2025. Stay tuned—the full video will be shared in the coming weeks. #Cancer #Oncology #MicrobiomeInnovation #Biotech #HealthcareTransformation
1
3
7